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A remarkable series of findings over the last decade or so has demonstrated a previously unrecognized role
for CNS glia in many aspects of neuronal functioning including pain processing. In addition to their recruit-
ment to sites of CNS damage, these cells also appear to be capable of ‘‘action at a distance,’’ playing func-
tional roles in areas of CNS that are quite remote from the focus of injury or disease. The implication is that the
nervous system is able to initiate signals that alter the function of these glial cells, and these cells in turn
release factors that regulate neuronal function. This idea has taken root, resulting in an explosion of research
interest, and here we look critically at what has been reported in order to assess where knowledge is missing
or uncertain.Introduction
Pain has long been recognized to be a complex sensory experi-
ence that varies not only with the nature and extent of tissue
injury, but also with a number of factors such as expectation,
emotional state, attention, and history. In some unusual circum-
stances, there is evidence that internal regulatory systems
(notably the sympathetic system) can modulate the pain experi-
ence (Day, 2008). In all of these cases, however, it has long been
assumed that purely neuronal systems are involved. The pain
signaling system is usually activated by activity in primary
sensory neurons that leads to coordinated activation of a series
of CNS areas (the so-called ‘‘pain-matrix’’—Tracey, 2007), and
pain modulation by physiological or psychological processes
has also mostly been envisaged as being executed through
neuronal control systems. It has long been recognized that a
variety of nonneuronal cells might play an important role in
initiating and modulating activity in primary afferent nociceptors
by the release of mediators that bind to specific receptors
expressed by those nociceptors. A particularly important source
of such mediators is cells of the immune system that are
recruited to the sites of peripheral injury and inflammation. The
relative lack of efficacy of cyclooxygenase (COX) inhibitors in
many chronic pain states, and encouraging clinical data on the
analgesic actions of, for instance, anti-NGF in some conditions
(T.J. Schnitzer, N.E. Lane, M.D. Smith, M. Brown, 2008, 12th
World Cong. On Pain, abstract; Katz et al., 2009), strongly
suggests that novel and important pain mediators are still to be
elucidated. However, there is another form of pain modulation
arising from nonneuronal cells that has been recognized and
investigated only recently. This is the influence of CNS glial cells
(which include some cells of the immune system, such as micro-
glia, but other cells that are not, notably astrocytes and oligoden-
drocytes) on pain processing. For several decades the biology of
these developmentally distinct cells has been explored, mostly
from the perspective of their presumptive support role for
neurons—providing metabolic homeostatis for the CNS, electri-
cal insulation to facilitate signal transmission and integrity, and,
in the case of microglia, immune surveillance cells for the CNS.
Of course, disease or injury directly affecting the CNS, such as
multiple sclerosis, is well recognized to sometimes lead to symp-46 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.toms because of effects on these cells. But a novel action of
these cells with an intriguing feature has emerged in pain pro-
cessing: their effects can arise at a distance, that is, in areas of
CNS that are quite remote from the focus of injury or disease.
The implication is that the nervous system is able to initiate the
signals that alter the function of these glial cells, and that when
recruited, these glial cells in turn regulate neuronal function.
This idea has taken root in the pain field and there has been an
explosion of research interest in the phenomenon in the last
5 years or so. This burgeoning interest is revealing a fascinating
series of neurobiological mechanisms, many of which have been
recently covered in excellent reviews (Abbadie et al., 2009; Inoue
and Tsuda, 2009; Milligan and Watkins, 2009; Romero-Sandoval
et al., 2008b; Scholz and Woolf, 2007). Yet as this field expands
and experimental data multiplies, it is perhaps worth looking
critically at what has been reported and at what may still be lack-
ing. To this end, the aim of this review is not to recap all the
experimental findings to date, but to focus on a series of ques-
tions where, it seems to us, critical knowledge is missing or
remains uncertain. As we will review in following sections, there
is considerable evidence from preclinical studies that central glia
can in some circumstances contribute critically to pain-related
behavior. The important question of how much is relevant to
humans, and what more could be done in the clinic, is consid-
ered at the end of this review.
What Is Glial ‘‘Activation?’’
The central thrust of the argument is that CNS glial cells are,
under normal conditions, bystanders in nociceptive processes
but that they become ‘‘activated’’ following damage to periph-
eral tissues or nerves, and in this state now release factors that
induce hyperexcitability in pain signaling pathways and thereby
contribute to abnormal pain perception. Figure 1 illustrates the
main features of this idea and shows two glial cell types, micro-
glia and astrocytes, that have been studied in this context, the
former much more than the latter.
Microglial cells exist in the parenchyma of the CNS and at peri-
vascular sites. These two types have distinct properties, but both
belong to the myelomonocytic lineage, which also includes
monocytes and macrophages. Unlike other cells of this lineage,
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10%–20% of glial cells in adulthood. Microglial cells have
distinct morphological and functional properties that are devel-
oped under the influence of nearby astroglia (which produce
colony stimulating factors) and neurons (which can modulate
microglial function via the release of neurotrophins that appear
to downregulate MHC class II expression via interaction with
p75 receptor) (Sievers et al., 1994).
In normal conditions, microglia perform immune surveillance
of the nervous system. They exhibit ramified processes that
are highly motile (Nimmerjahn et al., 2005) and express receptors
for complement components, Fcg receptor for IgG, and low
levels of cell-surface immune molecules. This status changes
dramatically not only following direct insults to the CNS, but
also quickly after injury to peripheral nerves or peripheral tissues.
Under these conditions, microglial morphology changes as cell
bodies increase in size; proximal processes become thicker
and distal branches appear less ramified. Microglia show
increased phagocytic activity, an enhanced migratory capacity
within the CNS, and increased expression of cell-surface glyco-
proteins including CD45 and MHC-II.
Astrocytes derive from the neuroectoderm and are intimately
associated with neuronal synapses because a single astrocyte
can make contact with several neurons. Astrocytes express a
large number of neurotransmitter receptors and can themselves
release transmitters, such as glutamate, D-serine, or ATP, uponelevation of intracellular calcium concentration. As astrocytes
communicate via gap junctions, the elevation of intracellular
calcium ions propagates among astrocyte networks indepen-
dently from neurons. In addition, astrocytes respond to ATP via
P2Y receptor activation, generation of IP3, and elevation of intra-
cellular calcium. They can modulate synaptic neurotransmission
and plasticity by exerting mGluR-mediated depression and
NMDA-mediated increase in neurotransmitter release (Haydon,
2001). Furthermore, astrocytes take up the majority of extracel-
lular glutamate via the glutamate transporter-1 (GLT1/EAAT2),
which is mainly located on these cells (Tanaka et al., 1997). As
with microglia, damage to peripheral nerves and peripheral
tissues alters the resting state of astrocytes, most prominently
near the central terminals of damaged sensory neurons (and
around motoneurons). This altered state is again referred to as
activation and is marked by an increase in GFAP expression.
The contribution of microglia and astrocytes to the develop-
ment of abnormal pain is considered below, but one important
issue for this field is to refine the simple dichotomy of ‘‘resting’’
and ‘‘activated’’ state. The case is most clear for microglia. In
the normal state, microglial cells are typically highly ramified
and their processes are highly motile to sample or survey the
healthy CNS. In many pathophysiological conditions they change
their morphology and can take on deramified forms. Associated
with this morphological change are many alterations in gene
expression in these cells, including the upregulation of a numberNeurons
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Figure 1. Pain-Related Enhanced Response States in Microglia and Astrocytes in the Dorsal Horn of the Spinal Cord
The figure illustrates the morphological changes seen in microglial cells (left) and astrocytes (right). The receptors involved in the shift from resting state to the
enhanced response states are shown in yellow ellipses. In the dorsal horn of the spinal cord, primary afferent terminal fibers release glutamate, substance P, and
brain-derived neurotrophic factor (BDNF), which activate their cognate receptors on postsynaptic dorsal horn neurons and transmit noxious input from the
periphery to higher centers. Following peripheral nerve or tissue injury, the transmission of pain-related signals is amplified although this is not itself considered
in this diagram. Alongside well-recognized neurotransmitters (glutamate, substance P, and BDNF, which activate second-order neurons), primary afferent fibers
release ATP and chemokines, such as CCL2, which activate their receptors on microglia and astrocytes, thereby inducing cell transition from bystander/surveil-
lance states to enhanced response states. Specific features of microglial and astrocytic responses are phosphorylation of MAK p38 and activation of JNK,
leading to the release of cytokines, chemokines, neurotrophins, and proteases that modulate neuronal activity and contribute to nociceptive processing.Neuron 64, October 15, 2009 ª2009 Elsevier Inc. 47
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and chemokine mediators and other released factors. It has
sometimes been assumed that there is a single ‘‘program’’ of
activation. But several lines of evidence suggest this is not the
case. As recently reviewed (Ransohoff and Perry, 2009), different
stimuli, engaging different microglial receptors, appear to lead to
distinct signaling cascades within the cells and different morpho-
logical or secretory consequences. For instance, glutamate
acting on microglial mGLUR2 receptors may selectively promote
TNFa production while UDP acting on P2Y receptors may selec-
tively lead to adoption of a phagocytic state. The particular reper-
toire of microglial responses may therefore vary with pain state
and temporal course. Less is known about astrocyte activation,
but it seems feasible, perhaps likely, that there will be a range
of metabolic responses in astrocytes too. For these reasons,
several recent reviews have made a plea to drop the term ‘‘acti-
vated glia’’ because it suggests a single state. We agree whole-
heartedly with this sentiment and suggest the term ‘‘pain-related
enhanced response states’’ to describe the different ways in
which glial cells might respond in these conditions. An enhanced
response state is evidenced both by increased expression of cell-
surface receptors in these cells and by increased secretion of
multiple factors. Some, but not all, of the phenotypic changes
in glial cells will be relevant to pain processing, and we use the
term ‘‘pain-related’’ to include those that are, even if the nature
of what is pain-related is still an open question in many cases.
A critical issue for this field is therefore to define more fully the
range of response states of these cells, perhaps most produc-
tively in terms of the receptors they express and the factors
they release. Comprehensive profiling of what is expressed by
these cells, at both mRNA and protein levels, under different
conditions is technically feasible.
What Is the Source of Glia that Show Pain-Related
Enhanced Response States?
After CNS injuries, microglia respond by rapidly entering the cell
cycle and undergoing local expansion (Ajami et al., 2007). This
type of reactive microgliosis is a hallmark of CNS pathologies
including stroke, neurodegenerative diseases, and demyelin-
ating inflammatory diseases. Reactive astrocytes play critical
roles in controlling extracellular glutamate concentrations and
intercellular communication, particularly about local injury (Rossi
et al., 2007). The number of microglial cells in the CNS also
dramatically increases in experimental pain models, especially
those involving injury to peripheral nerves. The number of astro-
cytes also increases although to a lesser extent than microglia
and at later time points after injury (Echeverry et al., 2008). Exten-
sive axonal degeneration appears to be a prerequisite for astro-
glial proliferation at the site of CNS injury. By contrast, after
peripheral nerve injury, microglial cell proliferation in the spinal
cord can occur in the absence of axonal degeneration (Liu
et al., 2000) or neuronal death (Polgar et al., 2005). Injury to the
rat facial nerve leads to mitotic divisions of microglial cells
without them developing into phagocytes, as well as changes
in their cytoskeletons and increased expression of complement
type 3 receptors (Moran and Graeber, 2004). Injury of rodent
sciatic nerve is also associated with microglial proliferation and
increased immunoreactivity for microglial markers such as48 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.OX-42 and astrocytic markers (GFAP) in the somatotopically
relevant areas in the spinal cord and brainstem and beyond
(see below).
Division of resident cells appears to account for at least some
of the increased glial cell numbers, but there is considerable
controversy concerning whether blood-derived monocytes also
contribute. In the case of direct CNS injury, disruption of the
blood-brain barrier facilitates the inward movement of hematog-
enous cells, but in the case of peripherally restricted injuries, it is
less clear to what extent this barrier function is compromised
(Gordh et al., 2006; Brooks et al., 2006). The issue has been
addressed with the use of chimeric animals in which circulating
monocytes, but not resident microglia cells, in a host animal are
tagged. Initial data from bone marrow of chimeric mice sug-
gested that hematogenous monocytes infiltrate the spinal cord
after peripheral nerve injury, proliferate, and differentiate into
microglia (Zhang et al., 2007). This is potentially more than of
academic interest because the claim that bone-marrow stem
cells can penetrate the damaged brain and spinal cord has raised
the hope of delivering genes to injured areas of the CNS.
However, recent reports raise the possibility that inflammatory
monocytes penetrate the CNS in chimeric mice because the irra-
diation preconditioning of the CNS (necessary in this experiment)
renders the BBB more permeable, suggesting reactive microglia
may not derive from the blood stream. This conclusion might not
be totally correct though because nerve injury is performed 3 to
5 months after irradiation, after which time the BBB is unlikely
to allow cell trafficking into the CNS. Furthermore, in a viral model
associated with negligible breakdown of the BBB, inflammatory
monocytes have been shown to penetrate the CNS rapidly and
differentiate into microglia (Getts et al., 2008).
The issue on whether immigrant microglia intermingle with
resident microglia after peripheral nerve injury remains intriguing
because these two cell populations (Carson et al., 2006) might
perform different roles in regulating neuronal function and
contribute differentially to pain modulation.
How Important Are Glial Cells to Chronic Pain?
There is considerable evidence that glial cells can contribute to
some experimental pain states, and that they indeed play an
essential role in some of these. However, there remains much
uncertainty as to the relative contribution of different types of
glial cells, and the temporal and spatial importance of glial cells
that develop enhanced response states. One concern is that we
have surprisingly few good tools to address these issues. Much
of the data available have been obtained by using rather general
glial inhibitors. The antibiotic and immunomodulator minocycline
has been extensively used as an inhibitor of glial cells. Its mech-
anisms of action remain somewhat uncertain, and suggestions
include reduction of microglial production of proinflammatory
factors such as NO and IL-1b (Lai and Todd, 2006). Fluoroace-
tate and its metabolite fluorocitrate are other commonly used
glial inhibitors. Low doses of fluorocitrate specifically and revers-
ibly disrupt microglial and astrocytic metabolism by blocking
aconitase, which is an enzyme found in the tricarboxylic acid
cycle of glia, but not that of neurons. A third general glial inhibitor
is propentophylline, which decreases microglial and astrocytic
responsiveness via mechanisms including increase in cAMP
Neuron
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ation of glutamate transporters (Tawfik et al., 2008a). L-alpha-
aminoadipate is a cytotoxin specific for astrocytes and produces
reduction of GFAP (Ji et al., 2006).
There are several potential problems with these inhibitors. The
first is one of specificity—they may have other important biolog-
ical actions that could contribute to their effectiveness. There
are already suggestions that these compounds can also affect
neurons, particularly in the case of high concentrations of fluoro-
citrate. A second problem is that the nonspecific inhibition of glial
cell function may not block all (or even any) of the pronociceptive
aspects of the enhanced response state of glia. As discussed
above, the different possible enhanced response states are
poorly defined at present and these general inhibitors may affect
only some of these functions. A failure to block abnormal pain
with these agents cannot be taken as definitive evidence that
a particular cell type is not actively contributing to the condition.
Notwithstanding these problems, there are multiple reports of
the effectiveness of these treatments, particularly propentofyl-
line, in models of chronic pain after nerve injury and cancer
chemotherapy-induced neuropathy (e,g. Sweitzer et al., 2006;
Tawfik et al., 2008a; Cata et al., 2008).
There are other interventions that target, at least under certain
conditions, processes that are specific for a particular glial cell
type. One example is cathepsin S (CatS), which is a lysosomal
enzyme expressed and released by microglia in the spinal
cord. CatS contributes to the maintenance of neuropathic hyper-
algesia and allodynia via the liberation of the pronociceptive
domain of neuronal chemokine fractalkine (FKN; also CX3CL1)
(Clark et al., 2007a, 2009). Relevantly, CatS inhibitors reverse
established neuropathic mechanical hyperalgesia following
acute administration as well after prolonged delivery over 5 days
(Irie et al., 2008), arguing for a specific role for spinal cord micro-
glia in this process.
Another example is the expression of complement compo-
nents in microglial cells that occurs rapidly after experimental
injury to peripheral nerves in areas of the central terminations
of the damaged nerve fibers. Complement component levels
decline gradually a few weeks after injury, returning to normal
levels by about 30 weeks in the spinal cord but remaining high
in the gracile nucleus (Liu et al., 1995; Griffin et al., 2007).
Blockade of complement 5 (C5) receptor reduces cold allodynia
in neuropathic rats, indicating that complement activation
converging on C5 contributes to the nocifensive response to
cold associated with nerve injury (Griffin et al., 2007). The deple-
tion of complement component C3 by intrathecal injection of
cobra venom factor also reportedly alleviates established allody-
nia in neuropathic pain models (Levin et al., 2008), suggesting
that inhibition of the complement pathway may be an effective
analgesic strategy.
A putative astrocytic target is intracellular signaling protein
c-jun-N-terminal kinase (JNK), which is activated by cytokines
such as TNFa and increases the expression of the chemokine
of CCL2 by astrocytes. In turn this chemokine enhances excit-
atory transmission in dorsal horn neurons expressing CCR2
receptors (Gao et al., 2009). Also in astrocytes, the upregulation
of the metalloproteinase MMP-2 can contribute to pain mecha-
nisms via production of IL-1b, thereby providing a non cas-pase-dependent source of this cytokine (Kawasaki et al.,
2008). Indeed, intrathecal delivery of either JNK or MMP-2 inhib-
itors reverses neuropathic allodynia (Ji et al., 2006; Kawasaki
et al., 2008; Gao et al., 2009).
These examples provide more confidence in the role of partic-
ular cell types in pain processing, but of course positive findings
will be limited to where the correct target has been selected and
where an unambiguous glial origin is demonstrable. A further
complication is that different glial cell types may play distinct
roles at different stages of disease progression. Indeed, there
is a growing acceptance of the idea that microglia may play a crit-
ical early role, but their importance appears to wane with time,
whereas astrocytes appear to play pronociceptive roles that
contribute to the persistence of chronic pain. Support for these
ideas comes from studies showing that pain-related enhanced
responsiveness in microglia peaks soon after peripheral nerve
injury and declines at later time points (Zhang and De Koninck,
2006). Pain-related enhanced responsiveness of astrocytes
occurs with some delay but persists and possibly outlasts the
enhanced responsiveness of microglia (Tanga et al., 2004).
However, some changes in microglial expression of surface
receptors have been observed as long as 50 days after nerve
injury and their inhibition by fluorocitrate and propentofylline
correlated with reversal of hyperalgesia (Clark et al., 2007b; Taw-
fik et al., 2007). Furthermore, in studies on pain after spinal cord
injury, there is evidence that enhanced response states of micro-
glia contribute to both the maintenance phase and induction
(Hains and Waxman, 2006). In any case, defining the role of
a particular cell type may require extensive temporal profiling.
In a similar vein, the spatial distribution of contributing glia has
not been extensively tested (Beggs and Salter, 2007). Most
work on pain has examined spinal cord, and more specifically
(and reasonably) the somatotopically appropriate areas of
cord. However, it is now clear that glial activation can occur at
more rostral sites in some of these peripheral nerve injury condi-
tions, although microgliosis is not ubiquitous in the brain in these
conditions, and microglial cells maintain a ramified morphology
in cortical area such as the anterior cingulate and the periaque-
ductal gray matter (PAG) (Zhang et al., 2008). Some specific
brain areas do, however, exhibit changes. Examples include
altered microglial responsiveness in the gracile nucleus, the
area of termination of the lesioned myelinated A fiber primary
sensory neurons. Reversal of allodynia has been reported by
infusion of p38 inhibitors in the gracile nucleus (Terayama
et al., 2008) and in the rostral ventromedial medulla (Wei et al.,
2008), and indeed, in thalamus after spinal cord injury (Zhao
et al., 2007). The use of systemically administered agents of
course fails to distinguish their effective site of action.
A useful starting point for investigations into glial function is
to consider when and where glial cells show enhanced respon-
siveness in different pain states, ideally of course using a
more comprehensive analysis of the nature of the altered
responsiveness (for instance, quantifying some of the mediators
released in this state as well as the sensitivity of the glial cells
to different stimuli). However, even on a rather superficial anal-
ysis, it appears that damage associated with peripheral nerve
injury is a more robust and consistent inducer of these enhanced
response states compared with peripheral inflammatoryNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 49
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matic injuries of peripheral nerves, in chemotherapy-induced
neuropathies, and in models of diabetic neuropathy, all workers
agree that microglial and astrocytic cells in the spinal cord
assume enhanced response states. Glia cells change mor-
phology (visualized by Iba-1 and GFAP staining, for microglia
and astrocytes, respectively) and microglia increase CD11b
expression (revealed with OX-42 staining) with a time course of
days to weeks—roughly concomitant with the presence of
hyperalgesia and allodynia (Zhang and De Koninck, 2006; Peters
et al., 2007 ; Wodarski et al.,2009). Consistent with the idea that
glial cells contribute to neuropathic pain, glial inhibitors prevent
and reverse pain response in all these models (Clark et al.,
2007b; Ji et al., 2006; Tawfik et al., 2008a, 2007; Hald et al.,
2008; Sweitzer et al., 2006).
In contrast, in models of peripheral inflammatory pain,
evidence for microglia and astrocyte involvement in nociception
is less substantial. The intraplantar injection of inflammogens
such as zymosan, formalin, and carrageenan are reported to
induce microglial expression of CD11b within hours, while intra-
plantar injection of complete Freund’s adjuvant, induces it within
a few days (Ledeboer et al., 2005; Clark et al., 2007b; Hua et al.,
2005; Sorkin et al., 2009; Svensson et al., 2007; Raghavendra
et al., 2004; Guo et al., 2007; Sun et al., 2007; Romero-Sandoval
et al., 2008a). However, the degree of glial change is typically
less well defined with these insults, although there is some
evidence that general glial inhibitors and inhibitors of chemokine
receptors (e.g., CX3CR1) can prevent some of the abnormal
sensory responses associated with inflammation. Also, whether
glial cells contribute to pain mechanisms in chronic inflammation
is unknown. It seems likely, but is unproven, that different factors
are responsible for initiating glial responses in neuropathic and
inflammatory states. In neuropathic conditions, there are known
to be marked changes in transmitters/modulators that are
expressed and released from sensory neurons, and it seems
likely that one or more of these may drive the enhanced response
state of glial cells (as we discuss more fully below). In inflamma-
tory conditions these transmitters/modulators are typically
upregulated in sensory neurons, and the rapid, but weaker, glial
responses that are seen appear to arise as a consequence of
ongoing neuronal activity and the release of constitutively ex-
pressed factors. Indeed, because of this, it seems likely—but is
again untested—that enhanced response states will be distinct
in these two conditions.
Overall, there is growing confidence that microglia and astro-
cytes play specific roles in pain processing, though the evidence
is more substantial for neuropathic pain than inflammatory pain.
Furthermore, microglia are the first nonneuronal cells showing
enhanced response state, while astrocytes follow with some
delay. The development of selective tools for targeting microglial
and astrocytic processes specifically involved in pain states
would certainly help clarify the importance of glial cells.
What Factors Increase the Responsiveness of Glial
Cells in Pain States and What Do These Cells Release
that Affects Pain Processing?
When the CNS is directly damaged there are many ways in which
signals might be generated that act on microglia and astrocytes.50 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.However, pain-related enhanced response states of glia often
arise following damage to peripheral tissues or nerves, and this
raises the question of what drives the altered glial responses in
these circumstances. Since the precipitating event in these
cases is peripheral damage, one obvious candidate is the
activity in primary sensory neurons and the attendant release
of neurotransmitters/modulators. These include classical trans-
mitters such as glutamate, substance P, and brain-derived
neurotrophic factor (BDNF), but also ATP, neuronal chemokines,
and yet unidentified activators of Toll receptors expressed by
glial cells.
Both glutamate and substance P, which are released in the
dorsal horn following activation of nociceptive neurons, are
capable of inducing changes in microglial cells and astrocytes.
The effects are direct, via activation of NMDA receptors and
NK1 receptors, on microglia (Rasley et al., 2002). Astrocytes
express low levels of NK1 receptors, which are upregulated in
reactive states (Palma et al., 1997; but see Guo et al., 2007) and
respond to glutamate and ATP. The microglia, which of course
are electrically unexcitable, show induction of the transcriptional
activator NF-kB following NK1 receptor stimulation (Rasley et al.,
2002). This signal is believed to regulate the synthesis of proin-
flammatory cytokines by the microglia. A third primary afferent
transmitter, BDNF (Pezet et al., 2002), could also activate trkB
receptors on spinal microglia cells, following its known release
from nociceptive fiber terminals. However, following peripheral
nerve injury (the best documented cause of pain-related
enhanced response states in central glial), it appears that the
major source of spinal BDNF becomes microglia themselves.
Indeed, microglia-released BDNF has been claimed to play an
important role in modulating neuronal activity by causing a depo-
larizing shift in the chloride reversal potential, which results in
GABAergic transmission being less inhibitory, and in some spinal
transmission systems, frankly excitatory (Coull et al., 2005). The
evidence that substance P and glutamate actually play a role in
altering the responsiveness of central glia in pain states is much
weaker. NK1 (or substance P) knockout animals do not exhibit
a dramatic phenotype in neuropathic pain models. And while
glutamate acting at NMDA receptors has a well-established
role in promoting increases in central excitability in numerous
pain states, it is difficult to determine the role of glial-expressed
NMDA receptors specifically. In the spinal cord, the dorso-ventral
distribution of glial cells showing these enhanced response
states in these pain models is much more widespread than the
termination patterns of nociceptive afferents (which are highly
concentrated in the superficial laminae of the cord). So if primary
afferent transmitters are important, they are unlikely to be trans-
mitters restricted to nociceptors.
Another potential mediator of neuronal-microglial and neu-
ronal-astrocytic communication is ATP. This can be released
with activity from primary sensory neurons, although it can also
be released from glial cells, and presumably from CNS neurons
too, which potentially complicates interpretation of experimental
data. There is considerable evidence for an important role of ATP
in pain processing after nerve injury, but it is much less clear what
receptors are involved, with different claims for microglial P2X4
or P2X7 receptors and the metabotropic receptor P2Y12 (Tsuda
et al., 2003a; Hughes et al., 2007; Tozaki-Saitoh et al., 2008).
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resting microglia conditions. Following peripheral nerve injury,
P2X4 receptors are upregulated in microglia in the dorsal horn
(Tsuda et al., 2003b) and contribute to the development of neuro-
pathic allodynia by inducing the release of BDNF (Coull et al.,
2005; Trang et al., 2009). The pharmacological evidence for the
critical role of P2X4 comes from the use of antagonists with over-
lapping profiles of P2X receptor antagonism supported by recent
evidence in P2X4 null mice, which do not develop mechanical
hypersensitivity after peripheral nerve injury (Ulmann et al.,
2008). However, because resting microglia do not express high
levels of P2X4, and because microglial morphological changes
evolve regardless of the absence of P2X4 receptors after nerve
injury (Ulmann et al., 2008), something else is necessary to
initiate and maintain the altered responsiveness of the glia. In
addition, the source of ATP that does act on P2X4 receptors in
pathological states has also not been established to be primary
sensory neurons.
The case for P2X7 comes in part from the pharmacology of
ATP receptors. High-dose ATP (mM) is needed to activate
P2X7 while low doses (sub-mM) activate P2X4 and P2Y12.
In vitro,ATP at 1 mM induces currents in microglia (and to a lesser
extent in neurons) and induces microglial chemotaxis (Wu and
Zhuo, 2008) under conditions in which glutamate and GABA
(also at 1 mM) fail to produce effects on microglia (while acting
on neurons). Activation of ATP receptors also causes rapid
calcium response in cultured microglia (Light et al., 2006), and
activation of P2X7 receptors produced release of cytokines
from microglia. Moreover, and critically, blocking P2X7 recep-
tors reportedly reverses neuropathic and inflammatory pain in
some conditions. It is possible that the functional receptor on
microglia is a heteromer of P2X4 and P2X7 subunits. An
intriguing possibility is that the P2X4 and P2X7 receptors play
different temporal roles, with the maintenance phase of micro-
glial enhanced responsiveness dependent on P2X7 receptors
and requiring high concentrations of extracellular ATP as associ-
ated with tissue stress. To further complicate matters, activation
of microglial P2Y12 receptors is associated with microglial
membrane ruffling, chemotaxis, movement of fine processes,
and, as recently reported, pain (Tozaki-Saitoh et al., 2008).
P2Y12 is not expressed by peripheral macrophages (Haynes
et al., 2006).
Two further candidates for important primary afferent trans-
mitters mediating neuronal-glial communication are the chemo-
kines CCL2 and FKN. The chemokine CCL2 is de novo
expressed in damaged sensory neurons in several neuropathic
pain models, as soon as 1 day after injury. Astrocytes also
upregulate this chemokine following activation with TNFa (Gao
et al., 2009). CCL2 is released with activity in damaged primary
afferent fibers in the dorsal horn of the spinal cord (Thacker
et al., 2009). The suggestion is that this chemokine stimulates
microglia via CCR2 receptors, and in support, it is reported
that intrathecal neutralizing antisera to CCL2 reduces some
aspects of enhanced responsiveness in glia cells and neuro-
pathic pain behavior in these models (Thacker et al., 2009). Since
all classes of damaged sensory neurons (i.e. large and small)
show de novo expression of CCL2, the dorso-ventral extent of
microglia showing enhanced responsiveness in the spinal cordis consistent with CCL2 mediation. CCR2 null mice fail to
develop neuropathic pain after nerve injury (Abbadie et al.,
2003), although the locus of action here is unknown. However,
there are some uncertainties still. One is that damaged sensory
neurons also express CCR2, so actions of CCL2 on cells other
than microglia are possible. A second is that in neuropathic
conditions, microglia express CCR2, but it is less clear if normal
glia do. Thus while the data suggest that CCL2 may be neces-
sary for the contribution of microglia to neuropathic pain devel-
opment, it is not known if this signal alone is sufficient.
The other chemokine, FKN, is a transmembrane protein that is
expressed in the cell bodies of sensory neurons in the dorsal root
ganglia (DRG) and intrinsic neurons in the dorsal horn, but not in
CNS endothelial cells (Cardona et al., 2008). The receptor for
FKN, CX3CR1, is uniquely expressed by microglia in the dorsal
horn (Verge et al., 2004) and activation of CX3CR1 is pronocicep-
tive because spinal injection of the chemokine domain of FKN is
proalgesic in wild-type, but not CX3CR1/, mice (Clark et al.,
2007a). Our own recent work has revealed that the chemokine
domain of spinal FKN is liberated by the cysteine protease
CatS, which is expressed and released by microglial cells (Clark
et al., 2009). The activation of CX3CR1 on microglia induces
phosphorylation of p38 MAP kinase, which is a prerequisite for
cytokine synthesis and release from microglial cells. Microglial
p38 can also be activated by other chemokines, cytokines,
and substance P, and lead to transcription of NF-kB and expres-
sion of IL-1, IL-6, and COX-2 enzyme. Relevantly, the inhibitors
of p38 are antiallodynic in neuropathic states (Ji and Suter,
2007) and antihyperalgesic in inflammatory states (Svensson
et al., 2003).
Alongside chemokine receptors, other receptors that can
increase glial cell responses in pain states are the Toll receptors,
which are expressed by a variety of cell types in the spinal cord.
But one receptor, TLR4, is selectively expressed on microglia.
TLR4 is required for the development of neuropathic allodynia,
which is very much attenuated in TLR4 null mice (Tanga et al.,
2005), but it is possible that this reflects a long-term alteration
in the properties of microglia in the absence of this receptor.
Alternatively, an endogenous ligand for TLR4 may be released
in these experimental pain models and contribute to the glial
response. The identity of this ligand is not known. However, acti-
vation of spinal TLR4 by an exogenous ligand (intrathecal injec-
tion of LPS) produces hyperalgesia and activation of p38 MAPK
in microglia without obvious neuronal damage (Clark et al.,
2006). Application of LPS to spinal cord slices induces rapid
release of IL-1b and activation of p38 with no requirement of
ATP as second stimulus, as is the case in microglia in culture
(Clark et al., 2006).
Together these data show that several stimuli can converge on
microglia and astrocytes and together generate or sustain
enhanced response states. These states appear to critically
involve signaling via p38 phosphorylation and NF-kB regulation
in microglia and JNK in astrocytes. What is not clear is which
of these stimuli, if any, is the initial precipitating cause of micro-
glial changes and why blocking any of so many factors prevents
the microglial and astrocytic response. Different factors may
play distinct roles under different conditions (e.g., different pain
models) or at different times. But it also appears clear that thereNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 51
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astrocytic responses. Microglia may both release and respond
to ATP and to BDNF; in neuropathic states, microglia release
CatS, which can release FKN from neuronal surfaces, which in
turn drives microglial responses via CX3CR1 receptors; some
of the cytokines released by microglia in these pain models,
such as TNFa, are able to stimulate these cells as well as
astrocytes and neurons. The presence of these feedback mech-
anisms may explain the sensitivity of microglial cells and astro-
cytes to multiple signals, each of which when blocked leads to
a progressive winding down of glial activity.
As reviewed above, multiple mediators can be released by
glial cells in their different states of enhanced responsiveness.
The inflammatory cytokines TNFa and IL-1b are frequently
reported. And indeed, there is good evidence that these
contribute to altered neuronal processing of painful stimuli in
the spinal cord. However, there is also evidence for the release
of other factors including ATP, NOS, prostanoids, BDNF, CatS,
MMP-2, MMP9, and several chemokines, including CCL2. Again
an issue for this field is defining the relative roles of these
different mediators in the modulation of pain processing.
Do Glial Cells Contribute to Chronic Pain in Humans?
The evidence and ideas reviewed in the sections above relate to
preclinical studies. While it is likely that some, perhaps much, will
translate to pain states in humans, this has not been formally
demonstrated, which is not surprising given the difficulty of
studying spinal glial cell function in humans. And it is also worth
remembering that not all findings do translate, as was unfortu-
nately the case recently in attempts to develop a drug targeting
CD-28 (see http://en.wikipedia.org/wiki/TGN1412).
The plain fact is that to date we have no direct evidence for
a role of central glia in human chronic pain states. One problem
is the difficulty of functionally studying these cells in humans.
One possible way to circumvent this is via the use of postmortem
material, and a recent study reports changes in microglia and
astrocytes in the posterior horns of the spinal cord of patients
with longstanding regional pain syndrome (Del Valle et al.,
2009). There are, however, some potential confounding factors
in this study. In this particular study the patients had been treated
with morphine for their ongoing pain conditions, but treatment
may have directly contributed to microglial changes. Moreover,
there were signs of neuronal loss in the posterior horn and a glial
response could have occurred as a result of this degeneration
rather than as a primary consequence of the peripheral pathology
precipitating the pain state. Nonetheless, these findings are
interesting in view of the observations that the levels of proin-
flammatory cytokines IL-1b and IL-6 are increased in the CSF of
some patients with chronic regional pain syndromes (Alexander
et al., 2005). Systemic and extensive studies are of course diffi-
cult with postmortem material. However, there are some special-
ized resources available, such as HIV-neuropathy related tissue
banks (e.g. http://www.neuro.jhmi.edu/HIV/researchers.htm)
that could be exploited to this end.
There are also some in vivo opportunities, perhaps the great-
est of which involves imaging techniques (Melzack, 2009). The
imaging of microglial status in pain states would be desirable
in both preclinical and clinical settings. The observation that52 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.the ‘‘peripheral benzodiazepine binding site’’ (PBD) protein
complex is not normally expressed by microglia, but becomes
upregulated in some pain states, may offer important opportuni-
ties, although PBD is not specific for microglia. One finding
consistent with this idea is that PBD binding to microglia in
the human thalamus increases many years after peripheral
nerve injury (Banati et al., 2001). Therefore, PET ligands for this
receptor may allow the state of microglial to be studied in vivo.
There also remains the possibility of exploiting other glial-
specific receptors and pathways to evaluate the contribution of
these cells in different pathologies in humans. However, nothing
to date has been described that is sufficiently selective to enable
unambiguous inferences to be drawn on glial function following
systemic treatment with appropriate ligands.
Concluding Remarks
The neurobiology of neuronal-glial interactions is emerging as
a fascinating and complex field. Such interactions are evident
in many contexts, but perhaps one of the most intriguing is in
the potential contribution to neuropathic pain originating from
peripheral nerve injuries. This field offers the opportunity to study
glial recruitment in the absence or presence of direct damage to
the CNS. New facts and new mechanisms are being revealed,
but as we have reviewed here, there remain numerous gaps in
our knowledge. Perhaps the most significant of these relates to
the clinical importance of current knowledge. Many of the exper-
imental pain states that have been studied are not commonly
seen clinically. Moreover, the preclinical studies have focused
for the most part on early time points, whereas the clinical
problem is usually greatly prolonged. We do not currently have
many methods to study the questions in humans. Nonetheless
this field offers clinical potential as well as academic interest.
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